173 related articles for article (PubMed ID: 9402851)
1. Subcutaneous low-molecular-weight heparin for treatment of Trousseau's syndrome.
Züger M; Demarmels Biasiutti F; Wuillemin WA; Furlan M; Lämmle B
Ann Hematol; 1997 Oct; 75(4):165-7. PubMed ID: 9402851
[TBL] [Abstract][Full Text] [Related]
2. [Recurrent thromboembolisms despite oral anticoagulation in a 76-year-old patient--Trousseau syndrome].
Züger M; Demarmels Biasiutti F
Ther Umsch; 1999 Sep; 56(9):481-3. PubMed ID: 10517113
[TBL] [Abstract][Full Text] [Related]
3. Continuous subcutaneous heparin infusion for treatment of Trousseau's syndrome.
Alderman CP; McClure AF; Jersmann HP; Scott SD
Ann Pharmacother; 1995; 29(7-8):710-3. PubMed ID: 8520087
[TBL] [Abstract][Full Text] [Related]
4. Lung adenocarcinoma complicated by Trousseau's syndrome successfully treated by a combination of anticoagulant therapy and chemotherapy.
Yoshii Y; Numata T; Ishitobi W; Takahashi N; Wakui H; Kojima J; Shimizu K; Hara H; Ishikawa T; Kawaishi M; Saito K; Araya J; Kaneko Y; Nakayama K; Kuwano K
Intern Med; 2014; 53(16):1835-9. PubMed ID: 25130121
[TBL] [Abstract][Full Text] [Related]
5. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis.
Belcaro G; Nicolaides AN; Cesarone MR; Laurora G; De Sanctis MT; Incandela L; Barsotti A; Corsi M; Vasdekis S; Christopoulos D; Lennox A; Malouf M
Angiology; 1999 Oct; 50(10):781-7. PubMed ID: 10535716
[TBL] [Abstract][Full Text] [Related]
6. Trousseau's syndrome. Devastating coagulopathy in the absence of heparin.
Bell WR; Starksen NF; Tong S; Porterfield JK
Am J Med; 1985 Oct; 79(4):423-30. PubMed ID: 4050830
[TBL] [Abstract][Full Text] [Related]
7. Low-molecular-weight heparin in the management of Trousseau's syndrome.
Walsh-McMonagle D; Green D
Cancer; 1997 Aug; 80(4):649-55. PubMed ID: 9264346
[TBL] [Abstract][Full Text] [Related]
8. Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.
Davis R; Faulds D
Drugs Aging; 1997 Apr; 10(4):299-322. PubMed ID: 9108990
[TBL] [Abstract][Full Text] [Related]
9. Trousseau's syndrome treated with long-term subcutaneous lepirudin (case report and review of the literature).
Andreescu AC; Cushman M; Hammond JM; Wood ME
J Thromb Thrombolysis; 2001 Feb; 11(1):33-7. PubMed ID: 11248788
[TBL] [Abstract][Full Text] [Related]
10. Left pneumonectomy for primary lung cancer with Trousseau's syndrome.
Ichinokawa H; Nagasaki Y; Koike Y; Suzuki K
BMJ Case Rep; 2021 Mar; 14(3):. PubMed ID: 33753389
[TBL] [Abstract][Full Text] [Related]
11. Trousseau's syndrome in association with ovarian carcinoma.
Evans TR; Mansi JL; Bevan DH
Cancer; 1996 Jun; 77(12):2544-9. PubMed ID: 8640704
[TBL] [Abstract][Full Text] [Related]
12. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis.
López-Beret P; Orgaz A; Fontcuberta J; Doblas M; Martinez A; Lozano G; Romero A
J Vasc Surg; 2001 Jan; 33(1):77-90. PubMed ID: 11137927
[TBL] [Abstract][Full Text] [Related]
13. [A Case of StageIV Gastric Cancer with Development of Trousseau's Syndrome during Neoadjuvant Chemotherapy].
Amasaki Y; Kuga T; Kunisue Y; Hirata K; Fujii Y; Nagatomi Y; Hamano K
Gan To Kagaku Ryoho; 2015 Aug; 42(8):1001-4. PubMed ID: 26321718
[TBL] [Abstract][Full Text] [Related]
14. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis.
Hirsh J
Haemostasis; 1996 Oct; 26 Suppl 4():189-98. PubMed ID: 8979124
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
[TBL] [Abstract][Full Text] [Related]
17. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?
Kaul S; Shah PK
J Am Coll Cardiol; 2000 Jun; 35(7):1699-712. PubMed ID: 10841215
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor.
Altman R; Scazziota A; Rouvier J
Haemostasis; 1998; 28(5):229-35. PubMed ID: 10420071
[TBL] [Abstract][Full Text] [Related]
20. [TROUSSEAU'S SYNDROME ACCOMPANIED BY ADVANCED PROSTATE CANCER THAT DEVELOPED ISCHEMIC STROKE; A CASE REPORT].
Kohada Y; Takemoto K; Goriki A; Kajiwara M
Nihon Hinyokika Gakkai Zasshi; 2019; 110(1):28-31. PubMed ID: 31956215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
